首页> 外文期刊>Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis >After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP).
【24h】

After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP).

机译:经过八年的宽容后,i.v。抗D输注可释放免疫性血小板减少性紫癜(ITP)患者的溶血作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Minimal doses of i.v. anti-D for ITP are not exempt from the risk of intravascular hemolysis, a rare potentially severe short-lived post-infusion complication. We report here on an elderly woman with chronic pancytopenia and splenomegaly in whom bleeding manifestations ceased after i.v. anti-Rh(D) immunoglobulin minidoses replaced long-term conventional treatment for immune thrombocytopenic purpura. Anti-Rh(D) infusions, that had been well tolerated for eight years, became the main culprit in triggering of disproportionate hemolysis. In spite of in crescendo complication, the anti-Rh(D) immunoglobulin schedule was maintained for another six months. With no further treatment, the patient's health remains stable 20 months later.
机译:静脉注射的最低剂量ITP的抗D药物不能免除血管内溶血的风险,血管内溶血是一种罕见的潜在严重的短暂短暂输注后并发症。我们在此报告了一名患有慢性全血细胞减少症和脾肿大的老年妇女,在静脉注射后出血表现停止。抗Rh(D)免疫球蛋白小剂量替代了免疫性血小板减少性紫癜的长期常规治疗。抗Rh(D)输注已经被很好地耐受了八年,成为引发不成比例的溶血的主要元凶。尽管并发症加重,抗Rh(D)免疫球蛋白方案仍维持了六个月。如果不进一步治疗,患者的健康状况将在20个月后保持稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号